Oculis Holding AG
NASDAQ:OCSBiotechnology
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
Volume 0.31M
Average 0.65M
OCS Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Oculis Holding AGNASDAQ: OCS
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -CHF 22.43M, compared with -CHF 19.97M a year earlier. Trailing-twelve-month operating income was -CHF 84.37M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of -CHF 73.85M (+6.7%) for the fiscal year ending Dec 2026, a step up from the -8.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CHF 22.43M-7.4% QoQ
- Last fiscal yearDec 2025
- -CHF 79.15M-8.1% YoY
- LTMMar 2026
- -CHF 84.37M-8.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.3% | -13.3% | -1.1 pp |
| 1 year | -8.1% | +6.7% | +14.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
CHF · from the income statement
- Latest · FY2025
- (79.15M) CHF
- Year-over-year change
- -8.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.15M) | -8.1% |
| FY2024 | 2024-12-31 | (73.2M) | +9.3% |
| FY2023 | 2023-12-31 | (80.71M) | -149.3% |
| FY2022 | 2022-12-31 | (32.38M) | -144.7% |
| FY2021 | 2021-12-31 | (13.23M) | — |
Operating Income vs competitors
How OCS compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -8.4% is the 4th highest of 6, against a peer median of +20.8%.
- Operating income amounts to 16741.0% of revenue for OCS, versus a peer median of 2138.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $28.12M USD | +522.3% | +172.0% | 10.5% | |
| FY2025 | -$7.19M USD | +54.2% | — | — | |
| LTM Mar 2026 | -$60.57M USD | +20.8% | — | 18182.8% | |
| LTM Mar 2026 | -CHF 84.37M CHF | -8.4% | — | 16741.0% | |
| LTM Mar 2026 | -$281.82M USD | -74.6% | — | 3700.9% | |
| LTM Mar 2026 | -$299.44M USD | -46.7% | — | 575.4% | |
| Peer median (excluding OCS) | — | +20.8% | +172.0% | 2138.2% | |
Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 686K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 52.08M | 0 |
| Gross Profit | 0 | 0 | 0 | (51.4M) | 0 |
| Gross Margin | — | — | — | -7492.3% | — |
| Research & Development | 9.57M | 22.22M | 29.25M | 52.08M | 54.52M |
| Selling, General & Admin | 4.1M | 6.74M | 14.72M | 21.81M | 24.63M |
| Operating Expenses | 13.23M | 32.38M | 80.71M | 21.81M | 79.15M |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 521.45K |
| EBITDA | (13.17M) | (31.9M) | (87.09M) | (85.53M) | (93.37M) |
| EBITDA Margin | — | — | — | -12468.1% | — |
| Operating Income | (13.23M) | (32.38M) | (80.71M) | (73.2M) | (79.15M) |
| Operating Margin | — | — | — | -10671.1% | — |
| Interest Income | 21K | 126K | 1.59M | 2.17M | 1.69M |
| Interest Expense | 5.12M | 6.44M | 1.46M | 639K | 795.55K |
| Other Income / Expenses | (5.29M) | (6.27M) | (7.98M) | (12.73M) | (15.54M) |
| Income Before Tax | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.69M) |
| Pre-Tax Margin | — | — | — | -12527.3% | — |
| Income Tax Expense | 27K | 55K | 107K | (160K) | 177.64K |
| Net Income | (18.55M) | (38.7M) | (88.8M) | (85.78M) | (94.51M) |
| Net Margin | — | — | — | -12503.9% | — |
| EPS (Basic) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| EPS (Diluted) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| Weighted Avg Shares | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
| Weighted Avg Shares (Diluted) | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
Oculis Holding AG
NASDAQ:OCS
Intrinsic Alpha fair value
Locked
Current Price
$7.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.